

**miR-200c suppression increases tau hyperphosphorylation by
targeting 14-3-3 γ in early stage of 5xFAD mouse model of
Alzheimer's disease**

Hyunjun Park^{1,2}, Yeong-Bae Lee^{2,3} and Keun-A Chang^{1,2,4,*}

¹Department of Health Sciences and Technology, Gachon Advanced Institute for Health Sciences and Technology (GAIHST), Gachon University, Incheon, 21999, Korea


²Neuroscience Research Institute, Gachon University, Incheon, 21565, Korea

³Department of Neurology, Gil Medical Center, College of Medicine, Gachon University, Incheon 21565, Korea

⁴Department of Pharmacology, College of Medicine, Gachon University, Incheon, 21999, Korea


*Correspondence: keuna705@gachon.ac.kr

Supplementary Figures




Supplementary figure 1. miR-200c regulates 14-3-3 γ expression in SH-SY5Y.

(A-B) After transfection of mimic or inhibitor in SH-SY5Y, expression of miR-200c was evaluated using RT-qPCR (n = 6-8). (C-F) The expression of 14-3-3 γ protein in SH-SY5Y after transfection of miR200-C mimic or inhibitor was analyzed by Western blotting. The immunoreactivity of p-GSK-3 β /GSK-3 β (D&F) was relatively quantified by image J, normalized to β -actin internal control (n = 10-11). Data represent the mean \pm SEM. Data were replicated in a minimum of independent three times cultured samples. * p <0.05 and ** p <0.01. Data of miR-200c expression were analyzed by one-way ANOVA test, and western blot data were analyzed student's T-test.



Supplementary figure 2. Changes in expressions of p-GSK-3β and p-tau by miR-200c mimic and inhibitor in SH-SY5Y.

(A-D) The expression of p-GSK-3β (Y216), GSK-3β protein in SH-SY5Y after transfection of miR200-C mimic (A-B) or inhibitor (C-D) were analyzed with Western blotting. The immunoreactivity of p-GSK-3β/GSK-3β (B&D) was relatively quantified by image J, normalized to β-actin internal control. (E-J) Expression of phosphorylated tau proteins (AT-8 and AT-180) and tau protein (Tau H-150) in SH-SY5Y after transfection of miR200-C mimic (E-G) or inhibitor (H-J) were analyzed with Western blotting. The immunoreactivities of AT-8/Tau H-150 (F&I), and AT-180/Tau H-150 (G&J) were relatively quantified by image J, normalized to GAPDH internal control. Data represent the mean ± SEM (n=7-8). Data were replicated in a minimum of independent three times cultured samples. * $p < 0.05$, ** $p < 0.01$, and ns = non-significant. All data were analyzed student's T-test.



Supplementary figure 3. GSK-3beta inhibitor reduces the GSK-3β phosphorylation.

(A) The expression of p-GSK-3β (Y216), GSK-3β protein in SH-SY5Y after treatment of GSK-3β inhibitor (AR-A014418, LiCl) were analyzed with Western blotting. (B-D) The immunoreactivity of p-GSK-3β (Y216) (B), GSK-3β (C), and p-GSK-3β/GSK-3β (D) were relatively quantified by image J, normalized to β-actin internal control. Data represent the mean ± SEM. Data were replicated in a minimum of independent three times cultured samples. ** $p < 0.01$, *** $p < 0.001$, and ns = non-significant. All data were analyzed one-way ANOVA test.